Latest Articles
GSK’s Phase 2 Trial on Dostarlimab for Endometrial Cancer: A Market Game Changer? - TipRanks
GSK’s Phase 2 Trial on Dostarlimab for Endometrial Cancer: A Market Game Changer? TipRanks
Published: July 25, 2025, 4:19 p.m.
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer - Journal of Translational Medicine
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer Journal of Translational Medicine
Published: July 24, 2025, 9:25 p.m.
Research uses AI to find pathologic and genetic basis for worse outcome of endometrial cancer in Black women - Medical Xpress
Research uses AI to find pathologic and genetic basis for worse outcome of endometrial cancer in Black women Medical Xpress
Published: July 24, 2025, 2:29 p.m.
RUBY Trial: Real-World Safety, Efficacy Analysis, and Quality of Life Considerations in Endometrial Cancer - OncLive
RUBY Trial: Real-World Safety, Efficacy Analysis, and Quality of Life Considerations in Endometrial Cancer OncLive
Published: July 24, 2025, 2:03 p.m.
SIENDO Study: Long-Term Safety and Efficacy of Selinexor Maintenance in Endometrial Cancer - OncLive
SIENDO Study: Long-Term Safety and Efficacy of Selinexor Maintenance in Endometrial Cancer OncLive
Published: July 24, 2025, 1:49 p.m.
New Emory research uses AI to find pathologic and genetic basis for worse outcome of endometrial cancer in Black women - Emory News Center
New Emory research uses AI to find pathologic and genetic basis for worse outcome of endometrial cancer in Black women Emory News Center
Published: July 23, 2025, 11:11 p.m.
Endometrial cancer on the rise among young women - MSN
Endometrial cancer on the rise among young women MSN
Published: July 23, 2025, 5 a.m.
Association Between Dysmenorrhea and Endometrial Cancer: A Mendelian Randomization Study.
Background: Dysmenorrhea is a common gynecological symptom among reproductive-aged women, associated with substantial pain and decreased quality of life. Previous studies have suggested that inflammatory and hormonal fluctuations linked to …
Published: July 23, 2025, midnight
NXF1 suppresses progression of endometrial cancer by interacting with the SRSF3 to regulate SP4 splicing.
Conventional treatments for advanced endometriosis often have limited efficacy due to chemotherapy resistance, recurrence, and metastasis. This study analyzed clinical specimens to investigate the role of NXF1 in endometrial cancer …
Published: July 22, 2025, midnight
AstraZeneca’s DESTINY-Endometrial01 Study: A New Hope for Endometrial Cancer Treatment - TipRanks
AstraZeneca’s DESTINY-Endometrial01 Study: A New Hope for Endometrial Cancer Treatment TipRanks
Published: July 18, 2025, 4:12 p.m.
Link copied to clipboard!